Repligen RGEN

Biotechnology, Healthcare

$176.93

−1.00%

Market cap: $10B
PE: 242×; 10y median 120×
Forward PE: n/m; not a meaningful number
Price to sales: 12.7×
EV/EBIT: 160×
Revenue, 12 months: $785.1M; +16% on a year ago
Net margin: 5.3%
Free cash flow yield: 1.1%

Repligen trades at 242× trailing earnings, pricier than 89% of the last ten years. Revenue was $785.1M over the last twelve months, up 16% on a year earlier with a 5% net margin.

Charts

Financials

Income statement for RGEN, by quarter
Income statement	Q3 FY23	Q4 FY23	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
	$141.2M−30%	$166.6M−11%	$153.2M−7%	$158.8M−0%	$154.9M+10%	$167.5M+1%	$169.2M+10%	$182.4M+15%	$188.8M+22%	$197.9M+18%	$194.3M+15%	$204.1M+12%
Cost of revenue	$104.6M+21%	$88.1M−3%	$76.4M−7%	$77.3M−3%	$77.4M−26%	$128.7M+46%	$77.8M+2%	$89.4M+16%	$88.3M+14%	$94.1M−27%	$86M+11%	$94.1M+5%
Gross profit	$36.6M−68%	$78.5M−18%	$76.8M−8%	$81.5M+2%	$77.5M+112%	$38.8M−51%	$91.4M+19%	$93M+14%	$100.5M+30%	$103.8M+167%	$108.3M+19%	$110M+18%
R&D	$10.6M+3%	$10.3M−8%	$11.2M−8%	$10.6M+9%	$9.7M−8%	$11.7M+14%	$12.1M+8%	$14M+32%	$14.2M+46%	$13.1M+12%	$14.5M+19%	$14.4M+3%
SG&A	$55.6M+4%	$57.6M+8%	$61.8M+10%	$65.5M+33%	$75.6M+36%	$60.5M+5%	$70.7M+14%	$70.9M+8%	$73.7M−3%	$74.4M+23%	$76.5M+8%	$76.6M+8%
	$4.7M−91%	$9.9M−80%	$3.8M−73%	$5.5M−72%	−$7.8M	−$36.5M	$6.6M+75%	$13.9M+154%	$16.8M	$17.9M	$15.9M+142%	$14M+1%
Interest expense	$408K+24%	$1.3M+373%	$5M+1133%	$5.1M+1145%	$5.1M+1155%	$5.5M+328%	$5.3M+4%	$5.4M+5%	$5.4M+6%	$5.5M+1%	$5.6M+6%	$5.7M+6%
Pre-tax income	$11.4M−76%	$1.9M−97%	$3.7M−80%	$9M−64%	−$1.1M	−$38.6M	$7.9M+115%	$18.2M+102%	$17.1M	$19.1M	$1.8M−78%	$14.2M−22%
	−$5.5M	$18.3M+330%	$399K−88%	$3.3M−35%	−$495K−91%	−$4.7M	$2.1M+430%	$3.3M+1%	$2.2M	$5.8M	−$6.6M	$9.1M+173%
Net income	$16.9M−58%	−$16.4M	$3.3M−79%	$5.7M−71%	−$654K	−$33.9M+106%	$5.8M+77%	$14.9M+160%	$14.9M	$13.3M	$8.3M+43%	$5M−66%
	$0.30−58%	−$0.29	$0.06−78%	$0.10−71%	−$0.01	−$0.60+107%	$0.10+67%	$0.26+160%	$0.26	$0.23	$0.15+50%	$0.09−65%
	56.9M−1%	55.8M−2%	56.5M−1%	56.4M−1%	56M−2%	56.1M+0%	56.6M+0%	56.5M+0%	56.5M+1%	56.7M+1%	56.7M+0%	56.6M+0%

Gross profit: 65 periods, Q2 FY10 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 7 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q4 FY10: share-days: the 9-month average less the 6-month, weighted by days. 6 periods, Q4 FY18 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23 and Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Biotechnology nearest Repligen's size, closest first.

Company	Market cap	PE	Its 10y median PE	Fwd PE	P/S	Revenue growth	Net margin
RGENRepligen	$10B	242×	120×	n/m	12.7×	+16%	5.3%
KRYSKrystal Biotech	$9.2B	39.0×	42.7×	n/m	20.9×	+23%	54.8%
TECHBIO-TECHNE	$11.4B	63.1×	61.6×	n/m	9.4×	−0%	15.0%
HALOHalozyme Therapeutics	$14.3B	37.5×	21.3×	n/m	8.6×	+41%	24.9%
NBIXNeurocrine Biosciences	$14.5B	20.9×	42.8×	n/m	4.3×	+34%	20.9%
EXELExelixis	$16B	20.3×	22.8×	n/m	6.6×	+9%	35.3%
INCYIncyte	$23.5B	14.7×	36.9×	49.5×	4.0×	+27%	27.7%
UTHRUnited Therapeutics	$25.2B	21.0×	14.1×	22.0×	8.0×	+2%	41.6%
ALNYAlnylam Pharmaceuticals	$30B	37.8×	69.2×	26.7×	6.2×	+95%	16.8%
ADMAAdma Biologics	$2.4B	15.3×	21.5×	n/m	4.7×	+8%	33.0%
ONCBeOne Medicines	$42.9B	67.6×	68.4×	48.1×	7.0×	+34%	10.7%
Peer median	$15.2B	29.3×	39.8×	37.4×	6.8×	+25%	26.3%